Brief Biography of the Directors
Mr. Dilip S. Shanghvi is a graduate in commerce from Calcutta University. He is the Chairman and Managing Director of Sun Pharmaceutical Industries Limited and founded that Company in 1982. He has extensive experience in the pharmaceutical industry. Mr. Shanghvi is actively involved in international pharmaceutical markets and research and development functions at SPARC Ltd. Under the leadership of Mr. Dilip S. Shanghvi, Sun Pharmaceutical Industries Ltd. has recorded an all-round growth in the business.
Mr. Sudhir V. Valia is a fellow Member of Institute of Chartered Accountants of India and carries more than two decades of taxation and finance experience. In addition to being on the board of directors of a number of companies, he is also on the Board of Directors of Sun Pharmaceutical Industries Limited. Mr. Valia joined Sun Pharmaceutical Industries Limited in 1994, prior to which he was in private taxation practice.
Dr. T. Rajamannar is an M. Sc. from University of Madras, Ph.D in Organic Chemistry from IIT Madras and P ost Doctoral from University of Zurich, Switzerland. He is a non- Executive Director of Sun Pharma Advanced Research Company Ltd. He has been associated with Sun Pharma since 1993. He is now Head- R&D of Sun Pharmaceutical Industries Ltd, prior to which he was Executive VP- R&D & Whole-time Director of Sun Pharma Advanced Research Company Ltd. He has extensive experience in the pharmaceutical Industry. He has 17 research publications in International Journals and over 200 patents applications filed to his credit. He is the recipient of CSIR Award from 1983 to 1988. He is a Council Member of Chemical Research Society of India and National Organic Symposium Trust.
Ms. Bhavna Doshi, independent director of the Company, has experience of over 30 years in the fields of taxation, accounting, restructuring and allied subjects. She is a qualified chartered accountant and also holds Masters Degree in Commerce from Mumbai University.
She is former partner of full member firm of KPMG in India. She is serving as independent director on the boards of several listed companies. She is actively associated with activities of Institute of Chartered Accountants of India and has served for four terms as elected Member of the Council and participated in formulation of accounting standards and research projects.
She is the only person from India to serve as a Member of the Compliance Advisory Panel of the International Federation of Accountants headquartered in New York. She has served on the Government Accounting Standards Advisory Board constituted by Comptroller and Auditor General of India.
Ms. Doshi was the President of the Indian Merchants' Chamber (IMC), a leading trade and industry Chamber in 2011-12. She also served as President of Ladies' Wing of the Chamber which works towards women empowerment. She has served as member of committees of CII and ASSOCHAM and was also a member of Group constituted by the Tax Administration Reforms Commission chaired by Dr. Parthasarathy Shome in 2014. She is also associated with various social sector projects.
Mr. Mark Simon is the co-founder of Torreya Partners where he leads the firms Biotech Advisory team and was recently involved in Compugen's $500mm+ oncology immunotherapy partnership with Bayer (2013). Mark continues to be highly active in advising a number of scientifically-oriented biotechnology Companies, typically making recommendations that involve a long-term, scientifically oriented perspective.
Mark has over 30 years of experience advising life sciences companies and has worked on over 175 financing, licensing, and M&A transactions with a value in excess of $50 billion.
Before co-founding Torreya, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup where he was involved with a team of 100 professionals. In his role, Mark was also involved in expanding Citigroup's global life sciences coverage in Europe and Japan. Before joining Citigroup, Mark spent a decade of his career at Robertson Stephens, where he mainly covered biotech sector and raised 45% of all biotech dollars and managed or co-managed 20% of all transactions from 1999 to 2001, making the Life Sciences franchise the No.1 revenue producer among the 7 industry groups at the firm.
Notable IPOs Mark either led or worked on include Abgenix, Affymetrix, Alkermes, Alnylam, Cor Therapeutics, Esperion, Genentech, Genzyme, Gilead, Given Imaging, Imclone, Medicines, Millennium, Neurocrine, Progenics, and Rigel. Mark also played an active role in some of the secondary offerings or convertible transactions include Allergan, Amgen, Bone Care International, Centocor, Cephalon, Chiron, Cubist, Dov, Endo, Human Genome Sciences, ICOS, Immunex, Martek, NPS, OSI, Pain Therapeutics, Protein Design Labs, Regeneron, Schering-Plough, and Wyeth.
Before moving into Investment Banking, Mark was a senior research analyst covering biotech industry at the firm where he was a Wall Street All-Star Analyst three years in a row. Mark began his career as a research associate at Kidder Peabody in New York covering biotech and healthcare services industries.
Mark holds a BA from Columbia College and a MBA from Harvard Business School.
Mark is a registered representative with Financial West Group.
Ferzaan Engineer, PhD, is Co-founder and Chairman of Cytecare Hospitals Pvt Ltd. He also serves as Co-founder and Jt. Chairman of Medwell Ventures Pvt Ltd, a company offering home healthcare services under the Nightingales brand. He is also a Director on the Board of Cytespace Research Pvt Ltd. Until 2010, Ferzaan served as CEO of Quintiles Research (India) Pvt Ltd and was a member of the Asia-Pacific Management Board of Quintiles. He has also served on the Board of Cenduit LLC. He is a Mentor at Escape Velocity Accelerator in Bangalore. A pharmacy graduate from the LM College in Ahmedabad, Ferzaan completed his PhD in Pharmaceutical Sciences from the College of Pharmacy at the University of South Carolina (USA). He attended executive management programmes at the Kenan-Flagler Business School (USA), IIMA (India) and INSEAD (France).
Ferzaan previously worked as Assistant Professor of Pharmaceutical Sciences in the United States, followed by an industry position as R&D head for Core Healthcare. Ferzaan has been a member of professional bodies such as AAPS and AACP. He received the AACP New Investigator's Award in 1990 and received research grants from the National Institutes of Health, USA. He has published papers in leading international journals and lectured at several international conferences and at management schools. He has served on the Advisory Board of the Indian Society for Clinical Research (ISCR) and has been a member of the CII National Committee on Drugs and Pharmaceuticals and the FICCI Pharmaceuticals and Biotechnology Committee.